Nektar Therapeutics NKTR Preferred Stock, Par or Stated Value Per Share
Preferred Stock, Par or Stated Value Per Share at other companies
Other financials
Where this comes from
Reported directly by Nektar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PreferredStockParOrStatedValuePerShare.
The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nektar Therapeutics's preferred stock, par or stated value per share.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nektar Therapeutics's preferred stock, par or stated value per share?
- Nektar Therapeutics (NKTR) reported preferred stock, par or stated value per share of $0 in Q1 2026.
- How has Nektar Therapeutics's preferred stock, par or stated value per share changed year-over-year?
- Nektar Therapeutics's preferred stock, par or stated value per share decreased by 0.0% year-over-year, from $0 to $0.
- What is the long-term trend for Nektar Therapeutics's preferred stock, par or stated value per share?
- Over 5 years (2020 to 2025), Nektar Therapeutics's preferred stock, par or stated value per share has grown at a 0.0% compound annual growth rate (CAGR), from $0 to $0.